Safety Outcomes / Neurological/Mental Health

((A-318)) (A-318) Early-life Antibiotic Exposure and the Risk of Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis

((A-319)) (A-319) Assessing the Risk of Neurodevelopmental Disorders in Children Prenatally Exposed to β-Lactam Antibiotics

((A-320)) (A-320) Evaluating the Impact of GLP-1RAs on Mental Health and Antidepressant Use: A Target Trial Emulation with Distributional NCO Calibration

((A-321)) (A-321) Risk of adverse opioid-related outcomes among adult Medicaid enrollees with new long-term prescription opioid use

((A-322)) (A-322) Associations between lisinopril and amlodipine use and risk of aneurysmal subarachnoid haemorrhage: A UK population-based cohort study

((A-323)) (A-323) Association Between 5alpha-Reductase Inhibitors and Risk of Developing Parkinson’s Disease in Patients with Benign Prostatic Hyperplasia: Evidence from a Prospective Cohort Study

((A-324)) (A-324) DARWIN EU® - A multi-national network cohort study of the effect of doxycycline versus active comparators on the risk of suicidality in individuals with acne

((A-325)) (A-325) Use of fluoroquinolones and the risk of seizures: a population-based cohort study

((A-326)) (A-326) A Collaborative Approach to Evaluate Risk Factors for a Rare Adverse Event Among Individuals with Multiple Sclerosis Exposed to Sphingosine 1-phosphate Receptor Modulators

((A-327)) (A-327) The risk of mortality in patients with Multiple Sclerosis treated with alemtuzumab compared to other disease modifying therapies: A cohort study with data from five countries